2024 Archives

2024

High-Risk/BCG Naïve: Treatment of Choice

Michael A. O’Donnell, MD, discusses BCG’s role as the standard treatment for non-muscle invasive bladder cancer (NMIBC).

Yair Lotan, MD, discusses urinary biomarkers and highlights their evolving role in bladder cancer detection and surveillance.

Alberto Vargas, MD, examines the integration of AI into prostate MRI, focusing on its current state, challenges, and future implications.

Sigrid V. Carlsson, MD, PhD, MPH, explores the role of genetics in risk-stratified prostate cancer screening.

William K. Oh, MD, explores neuroendocrine prostate cancer, emphasizing its increasing prevalence and aggressive nature.